Mirum Pharmaceuticals, Inc. has announced its financial results for the third quarter of 2026, showcasing a robust performance that has led the company to raise its full-year sales guidance. The announcement comes at a pivotal time for the company, as it continues to expand its footprint in the rare disease market.

Mirum, which operates in the pharmaceutical preparations sector, reported net product sales of $185.7 million for Q3 2026, a significant increase compared to previous quarters. The company has now adjusted its full-year sales guidance to between $715 million and $720 million, indicating strong momentum in its commercial operations.

According to the filing made on November 3, 2026, Mirum's CEO, Chris Peetz, stated, “The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio.” This statement underscores the company's strategic focus on rare diseases, which is expected to drive future growth.

Background

Mirum Pharmaceuticals, Inc. is incorporated in Delaware and trades on the Nasdaq under the ticker symbol MIRM. The company specializes in the development and commercialization of treatments for rare diseases, particularly those affecting the liver. As a large accelerated filer, Mirum is subject to stringent reporting requirements, and its recent filings reflect ongoing developments in its product pipeline.

What the Filing Says

The filing reveals that Mirum has successfully launched ATEBRIOZ, a new treatment for fibrodysplasia ossificans progressiva (FOP), and has received FDA approval for the same. Additionally, the company reported positive outcomes from clinical trials for several of its products, including LIVMARLI and brelovitug, which are aimed at treating rare liver diseases.

Mirum's press release, included as Exhibit 99.1 in the filing, emphasizes the company’s commitment to addressing unmet medical needs and highlights the positive trajectory of its product sales and clinical advancements.

Impact

The results reported by Mirum may significantly affect various stakeholders, including investors, healthcare professionals, and patients. The increased sales guidance reflects not only the company's successful product launches but also its strategic positioning within the pharmaceutical preparations industry. Competitors may need to reassess their strategies in light of Mirum's expanding market presence and recent successes.

What's Next

Looking ahead, Mirum plans to continue its momentum with additional product launches and regulatory submissions. The filing does not specify exact future steps, but the company is expected to maintain its focus on advancing its pipeline and enhancing its market share in the rare disease sector.

For more details, the full press release can be accessed through the SEC filing, accession number 0001759425-26-000061.